Treatment shows promise as adjunctive calciphylaxis therapy

02/14/2013 | Healio

Thrombolytic tissue plasminogen activator was associated with a 30% increase in the survival rate for patients with calciphylaxis, according to a study in the journal JAMA Dermatology. Complications included major and minor bleeding, and six out of 15 patients had blood transfusions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC